The estimated Net Worth of Michel Bouchard is at least $13.9 Milión dollars as of 30 August 2017. Michel Bouchard owns over 5,390 units of Illumina Inc stock worth over $1,296,609 and over the last 12 years Michel sold ILMN stock worth over $12,648,860.
Michel has made over 40 trades of the Illumina Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Michel sold 5,390 units of ILMN stock worth $1,089,373 on 30 August 2017.
The largest trade Michel's ever made was selling 24,505 units of Illumina Inc stock on 25 February 2014 worth over $4,316,066. On average, Michel trades about 2,304 units every 26 days since 2013. As of 30 August 2017 Michel still owns at least 10,387 units of Illumina Inc stock.
You can see the complete history of Michel Bouchard stock trades at the bottom of the page.
Michel's mailing address filed with the SEC is 5200 ILLUMINA WAY, , SAN DIEGO, CA, 92122.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley a Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: